ClinicalTrials.gg
RecruitingNCT07185269Updated Nov 26, 2025

The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

A Phase 1/2 interventional study of 626 and 626 in Systemic Lupus Erythematosus (SLE), sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
42nd of 245
198 · median 36
Started
2025
with 61 others
Phase 1/2
19 of 266
13 open now
Primary completion
2028-08
later than 158 of 190 live
Registered
193rd of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 42nd largest by planned enrollment of the 245 interventional ones that give a count, is one of 62 that started in 2025, is one of 19 in phase 1/2, reaches primary completion later than 158 of the 190 other live ones, and was the 193rd registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the effect and safety of 626 in patients with SLE

Read the detailed description

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with heterogeneous manifestations and disease course. Despite advances in medical care, there are still significant unmet needs in SLE with persistent disease activity, disease flares, intolerance to standard of care (SOC) therapies, and development of organ damage and co-morbidities.

The purpose of this study is to demonstrate the clinical efficacy and safety of 626 added to standard of care (SoC) therapy compared to placebo with SoC therapy in subjects with SLE.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand protocol requirements and sign a written ICF.
  • Male or female subjects aged 18-70 years when signing the ICF.
  • Body weight between 40 and 90 kg.
  • Diagnosed with SLE at least 6 months before the Screening Visit by a qualified physician,confirmed according to the 2019 SLE European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE.
  • At screening, meet at least one of the following criteria:

    1. Anti-nuclear antibody (ANA) titer ≥ 1:80;
    2. Positive anti-dsDNA antibody..
  • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) ≥6 with clinical SLEDAI score ≥4 points at Screening and Baseline Visit .
  • Currently receiving at least one of the SOC SLE medications: oral , antimalarial and/or agent.

Exclusion criteria

Exclusion Criteria:

  • Study participant has a mixed connective tissue disease, and/or overlap syndrome of systemic lupus erythematosus (SLE) with systemic sclerosis.
  • Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric SLE) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition
  • Patients who have active , or infections as determined by positive results at Screening.
  • History of cancer.
  • Active severe lupus nephritis present within 2 months prior to baseline. Or estimated (eGFR) \<30 mL/min/1.73m2, or protein:creatinine ratio >2.0 g/g.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    Group M1

    dose level 1 of 626

    Drug: 626 · Drug: Placebo

  • Experimental
    Group M2

    dose level 2 of 626

    Drug: 626 · Drug: Placebo

  • Experimental
    Group M3

    dose level 3 of 626

    Drug: 626 · Drug: Placebo

  • Experimental
    Group M4

    dose level 4 of 626

    Drug: 626 · Drug: Placebo

  • Experimental
    626 Dose A

    626 Dose A subcutaneous (SC) injection.

    Drug: 626

  • Experimental
    626 Dose B

    626 Dose B subcutaneous (SC) injection

    Drug: 626

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

Interventions

  • Drug626

    626 subcutaneous (SC) injection. Placebo subcutaneous (SC) injection.

  • Drug626

    626 subcutaneous (SC) injection.

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events

    Incidence of adverse events will be summarized by SOC and PT for each treatment group, and also be summarized by severity and association with the study treatments.

    Time frame: During the 32- or 36-week study period

Secondary outcomes

  1. SLE Responder Index (SRI-4)

    Proportion of subjects achieving an SLE Responder Index (SRI-4) response

    Time frame: During the 20- or 24-week treatment period

  2. BILAG-based Combined Lupus Assessment (BICLA) Response

    Proportion of patients achieving a BILAG-based Combined Lupus Assessment (BICLA) response

    Time frame: During the 20- or 24-week treatment period

Other outcomes

  1. Peak Plasma Concentration (Cmax)

    Time frame: During the 32- or 36-week study period

  2. Area under the Concentration-Time Curve up to the Last Measurable Concentration(AUC0-last)

    Time frame: During the 32- or 36-week study period

  3. Time to Peak Concentration(Tmax )

    Time frame: During the 32- or 36-week study period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2028, 34 months after the start.

Of 38 phase 1/2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 22, 2025
StartActual
Sep 24, 2025
Primary completionEst.
Aug 12, 2028
CompletionEst.
Nov 4, 2028
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185269
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Sep 24, 2025
Primary completion
Aug 12, 2028 (estimated)
Completion
Nov 4, 2028 (estimated)
Last update
Nov 26, 2025

Study contacts

Qinghong Zhou
Contact
zhouqinghong@3sbio.com
+86 18911301578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion